Hyperphosphatemia
📧 Sign up to get email alerts when something new happens for Hyperphosphatemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-10-09Clinical Trial Update: A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) [Phase 2]
Phase 2 safety and tolerability results for ferric citrate (Zerenex) in patients with end-stage renal disease and hyperphosphatemia; the tri…
-
CLINICAL_TRIALS trial_result · 2014-10-06Clinical Trial Update: A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia [Phase 3]
Phase 3 trial of MCI-196 in chronic kidney disease patients on dialysis with hyperphosphatemia and dyslipidemia completed; results posted in…
-
FDA approval · 2014-10-06FDA Approved: CALCIUM ACETATE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approves Amneal Pharmaceuticals of New York LLC's calcium acetate under an Original Application (ANDA) as a generic phosphate binder to …
-
FDA approval · 2014-09-24FDA Approved: FOSRENOL — Original Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved Fosrenol (lanthanum carbonate) through Takeda's original NDA to treat hyperphosphatemia in adults with chronic kidney disea…
-
FDA approval · 2014-09-24FDA Approved: FOSRENOL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Fosrenol (lanthanum carbonate) submitted by Takeda Pharmaceuticals America, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2014-09-24FDA Approved: VELPHORO — Supplemental Application (Fresenius Medical Care Renal Therapies Group, LLC)
The FDA approved a supplemental application for Velphoro (sucroferric oxyhydroxide) from Fresenius Medical Care Renal Therapies Group, LLC.
-
CLINICAL_TRIALS trial_result · 2014-09-23Clinical Trial Update: A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia [Phase 3]
Phase 3 study of MCI-196 in chronic kidney disease patients on dialysis with hyperphosphatemia completed; results posted in 2014.
-
FDA approval · 2014-09-05FDA Approved: FERRIC CITRATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Ferric Citrate from Mylan as an original application to treat hyperphosphatemia in adults with chronic kidney disease on dialys…
-
CLINICAL_TRIALS trial_result · 2014-08-18Clinical Trial Update: Phosphate Kinetic Modeling 2 [Phase 4]
This update notes the completion of a Phase 4 clinical trial called Phosphate Kinetic Modeling 2, sponsored by Fresenius Medical Care North …
-
CLINICAL_TRIALS research · 2014-08-18Clinical Trial Update: Phosphate Kinetic Modeling [NA]
This document reports the completion of a clinical trial on phosphate kinetic modeling in patients with end-stage renal disease and hyperpho…
-
CLINICAL_TRIALS trial_result · 2014-08-05Clinical Trial Update: Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients [Phase 4]
Phase 4 long-term evaluation comparing sevelamer hydrochloride with a calcium-based phosphate binder in hyperphosphatemia among hemodialysis…
-
CLINICAL_TRIALS trial_result · 2014-07-25Clinical Trial Update: A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia [Phase 3]
A Phase 3, randomized, double-blind, placebo-controlled withdrawal study of MCI-196 in chronic kidney disease patients on dialysis with hype…
-
CLINICAL_TRIALS trial_result · 2014-07-16Clinical Trial Update: A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis [Phase 3]
A Phase 3 trial evaluating ASP1585 in chronic kidney disease patients with hyperphosphatemia not on dialysis has completed.
-
CLINICAL_TRIALS trial_result · 2014-06-23Clinical Trial Update: Bioequivalence Study of BAY77-1931 Granule [Phase 1]
This document reports the completion of a Phase 1 bioequivalence study of BAY77-1931 Granule for hyperphosphatemia.
-
CLINICAL_TRIALS trial_result · 2014-06-20Clinical Trial Update: Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone [Phase 2]
Phase 2 study evaluating long-term lanthanum carbonate treatment in hyperphosphatemia patients on dialysis to measure lanthanum concentratio…
-
CLINICAL_TRIALS trial_result · 2014-05-12Clinical Trial Update: Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia [Phase 3]
Phase 3 study of MCI-196 in patients with chronic kidney disease on dialysis and hyperphosphatemia has completed; results were posted in 201…
-
FDA approval · 2013-11-27FDA Approved: VELPHORO — Original Application (Fresenius Medical Care Renal Therapies Group, LLC)
FDA approved Velphoro (sucroferric oxyhydroxide) under an original NDA for the treatment of hyperphosphatemia in adults with chronic kidney …
-
CLINICAL_TRIALS trial_result · 2013-05-15Clinical Trial Update: The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients
A completed clinical trial evaluated the effect of magnesium oxide on plasma phosphate levels in hemodialysis patients with hyperphosphatemi…
-
FDA approval · 2013-02-07FDA Approved: CALCIUM ACETATE — Original Application (Cipla USA Inc.,)
The FDA approved Cipla USA Inc.'s original application for Calcium Acetate (generic calcium acetate).
-
FDA approval · 2013-02-05FDA Approved: CALCIUM ACETATE — Original Application (Chartwell RX LLC)
FDA approves Chartwell RX LLC's calcium acetate as a new generic phosphate binder under an Original Application (ANDA 202420).
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: BAY 77-1931 Long-term Extension From Phase II Study [Phase 2]
Update on the long-term extension of BAY 77-1931 from a Phase II trial in hyperphosphatemia, including interim safety/tolerability observati…
-
FDA approval · 2012-10-31FDA Approved: FOSRENOL — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Fosrenol (lanthanum carbonate) filed by Takeda Pharmaceuticals America, expanding the product's …
-
CLINICAL_TRIALS withdrawal · 2012-09-26Clinical Trial Update: Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD) [NA]
Clinical trial evaluating the effect of sevelamer on glucose tolerance and insulin sensitivity in chronic kidney disease was withdrawn.
-
CLINICAL_TRIALS trial_result · 2012-06-08Clinical Trial Update: Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium Carbonate [Phase 3]
A Phase 3 double-blind trial comparing lanthanum carbonate (BAY77-1931) with calcium carbonate for hyperphosphatemia has completed. The stud…
-
CLINICAL_TRIALS trial_result · 2012-06-01Clinical Trial Update: A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia [Phase 2]
Phase 2 study evaluating HS219 in chronic kidney disease patients on hemodialysis with hyperphosphatemia; the trial completed and results we…